The username/email didn't match the password, please try again!

Forgot your password?

The email you have inserted is not registered at Medicon Valley Online. If you wish to gain access to a specific organization profile please speak to one of the registered contacts of that organization. The registered contacts can usually be found on the profile page of that organization.

The email you have inserted is not in our database. Plese try again!

To add a compound to a pipeline your organisation needs to be registered as a biotech or pharmaceutical company at Medicon Valley Online. If your organisation is already registered please click on the Sign in button below. If you wish to register a new organisation, please click the Register button.

To add a service your organisation needs to be registered at Medicon Valley Online as a member of Medicon Valley Alliance and have paid the one time fee of 2300 EUR for the service section. If this has been accomplished please, just click the Sign in button below. If you want access to the services section or media about it please send your contact details to contact@mediconvalleyonline.com and we will get back to you.

Email
Password

(Uncheck if on a shared computer)
Forgot your password?
Create Account
Please enter your email address in the field below. Once submitted a message, with an authorization link, will be sent to this address so that you can set a new password for your account. You will have access to you account again in a couple of minutes. Thank you for your patience.
Medicon Valley Online
Home
 
Organisations
 
Drug Pipeline
 
Contract Services
 
Job Market
View all organisations

BioInvent International AB

Biotech Company / Biological Products

Pipeline
Staff
Contact
MVA
Member of Medicon Valley Alliance

description Description

BioInvent International AB focuses on developing antibody drugs. The proprietary fully human Ab library n-CoDeR and in-house cGMP manufacturing form a powerful platform for Ab drug development. Together with partners such as Roche, Genentech, Bayer HealthCare, ThromboGenics and UCB, BioInvent runs projects within the areas of thrombosis, cancer and atherosclerosis.

Drug Pipeline


compound BI-204 [Internal project]

BI-204 is a human antibody which targets the oxidised form of a low-density lipoprotein (LDL), called apoB100. BI-204 is being developed as a treatment for atherosclerosis, aimed at reducing the occurrence of heart attacks in high-risk patients. These are primarily patients with acute coronary artery disease, particularly those who have already suffered a heart attack. GLACIER was a randomized, placebo-controlled, double-blind,multicentre phase II study, where BI-204 was delivered intravenously to patients with stable coronary artery disease on top of standard-of-care. In July 2012 BioInvent annonced that the study did not meet the primary endpoint.

Read more about BI-204 go

Drug development

Therapeutical Area / Indication Pre-
clinical
Phase
I
Phase
II
Phase
III
Phase
IV
Heart and Blood Diseases
primary Atherosclerosis Pre-clinical Phase I Phase II Phase III Phase IV

compound TB-403 [Co-developed with Roche]

TB-403 is a humanised monoclonal antibody that blocks the activity of Placenta Growth Factor (PlGF), a protein involved in the development of new blood vessels (angiogenesis). TB-403's ability to block the growth of new blood vessels and modulate inflammation means it could potentially be used in a broad range of cancer and non-cancer indications.

Read more about TB-403 go

Drug development

Therapeutical Area / Indication Pre-
clinical
Phase
I
Phase
II
Phase
III
Phase
IV
Cancers and Other Neoplasms
primary Glioblastoma Pre-clinical Phase I Phase II Phase III Phase IV

compound BI-505 [Internal project]

BI-505 is a fully human antibody derived from BioInvent's proprietary n-CoDeR® library. The antibody binds to the adhesion protein ICAM-1 (CD54), which is over expressed in several tumours but is not widely expressed in normal tissue. BI-505 is being developed to treat multiple myelomas that express ICAM-1. BI-505 has been granted orphan drug designation for the treatment of multiple myeloma by both the FDA and the European Agency for the Evaluation of Medicines (EMEA).

Read more about BI-505 go

Drug development

Therapeutical Area / Indication Pre-
clinical
Phase
I
Phase
II
Phase
III
Phase
IV
Cancers and Other Neoplasms
primary Multiple Myeloma Pre-clinical Phase I Phase II Phase III Phase IV

Staff Top top


Eva Kullenstein
Eva Kullenstein
Director Human Resources
eva.kullenstein@bioinvent.com
+46 (46) 286 85 50 (Office)
vCard

Contact Top top


BioInvent International AB
Tel: +46 46 286 85 50
Fax: +46 (46) 211 08 06
http://www.bioinvent.com

Address:
Sölvegatan 41
SE-223 70
Lund
Sweden
©2010 Medicon Valley Online - Brought to you by Medicon Valley Alliance. All rights reserved.